arrow
A

Amy K. Taylor

harvard university medical affiliates
H指数:17
被引数:1,282

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

OUTCOMES FOR LOCALIZED RENAL CELL CARCINOMA IN SOLID ORGAN TRANSPLANT RECIPIENTS IS COMPARABLE TO NON-TRANSPLANT RECIPIENTS

局部肾细胞癌在实体器官移植受者中的预后与非移植受者相当

2026-05-010
PRE
COMPARISON OF PROSTATE CANCER YIELD PER MRI TARGET LESION FOR LATP VERSUS TRUS PROSTATE BIOPSY: NEW INSIGHTS FROM THE TRANSLATE RANDOMISED CLINICAL TRIAL

LATP与TRUS前列腺活检在每例MRI目标病灶中的前列腺癌检出率比较:来自TRANSLATE随机临床试验的新见解

2026-05-010
PRE
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study

在恩沃利单抗之后的尿路上皮癌患者中,萨cituzumab govitecan的疗效:UNITE研究的分析

2025-12-010
OAAI
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study

FGFR3突变型晚期尿路上皮癌中,erdafitinib在enfortumab vedotin治疗前或治疗后的疗效:UNITE协作研究的分析

2025-11-010
PRE
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

cfDNA片段组学指标分析与商业靶向测序面板

2025-10-140
OAAI
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study

接受恩沃利单抗维多汀治疗的晚期尿路上皮癌患者中的治疗相关不良事件及关联结局:UNITE研究的分析

2025-10-020
OAAI
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study

恩福妥单抗(Enfortumab Vedotin)在具有不同组织学亚型的晚期尿路上皮癌患者中的疗效:UNITE研究的分析

2025-09-140
PRE
Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer

转移性去势抵抗性前列腺癌的不良预后基因表达模式

2025-02-220
OAAI
Clinical cell-surface targets in metastatic and primary solid cancers
2024-09-240
OA
A platform-independent AI tumor lineage and site (ATLAS) classifier
2024-03-130
OAAI
ASO Visual Abstract: Association of Neighborhood Disadvantage with Short- and Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma
2023-10-080
PRE
Fragmentomic analysis of circulating tumor DNA-targeted cancer panels
2023-09-0110
PRE